Therapy Trends KOL Insight: Atopic Dermatitis
What advantages do KOLs see for Eli Lilly & Co/Almirall's pipeline lebrikizumab and what are its competitive prospects against AstraZeneca/Leo Pharma's tralokinumab and Sanofi/Regeneron's established Dupixent in the first line setting? Despite their impressive efficacy, why do KOLs have concerns about JAK inhibitors such as Pfizer's abrocitinib and AbbVie's Rinvoq? US and European KOLs critically assess the prospects of launched and pipeline therapies.
|Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.|
Key questions answered
- Do KOLs believe that the recent FDA approval of Sanofi/Regeneron's Dupixent for six- to 11-year-olds will expand use and solidify the product's first line position?
- What insights do KOLs have for AstraZeneca/Leo Pharma if tralokinumab is to effectively compete with Dupixent?
- In what settings do KOLs see potential for Incyte's topical JAK inhibitor, ruxolitinib?
- Why are KOLs pessimistic about Galderma/Chugai/Maruho's anti-IL31 mAb nemolizumab and Vanda Pharmaceuticals' small molecule neurokinin 1 (NK1) receptor antagonist tradipitant?
Examples of Therapies Covered
Partial List of Participating KOLs
|We engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.|
|Our-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.|
|Our reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.|
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.